Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharm Ord (NQ: AUPH )

12.35 USD -0.25 (-1.98%)
Official Closing Price Updated: 7:44 PM EDT, Apr 16, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,453,000
Open 12.66
Bid (Size) 12.37 (11)
Ask (Size) 12.40 (14)
Prev. Close 12.60
Today's Range 12.34 - 12.66
52wk Range 12.01 - 20.50
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in a fireside chat during the 2021 Bloom Burton &... 
From Business Wire News Releases
Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today presented additional efficacy data from the AURA-LV and AURORA 1 pivotal trials of LUPKYNIS™ (voclosporin) in lupus... 
From Business Wire News Releases

Performance

YTD
-8.79%
-8.79%
1 Month
-9.46%
-9.46%
3 Month
-9.39%
-9.39%
6 Month
-20.73%
-20.73%
1 Year
-25.11%
-25.11%

More News

Read More
Aurinia Announces Positive Cost-Effectiveness Assessment of LUPKYNIS™ (voclosporin) in Latest ICER Draft Evidence Report
From Business Wire News Releases
Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences
From Business Wire News Releases
Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights
From Business Wire News Releases
Aurinia's Lupkynis Shows Treatment Benefit In Lupus Nephritis, Additional Efficacy Data Shows
Tags Biotech AUPH General
From Benzinga
Aurinia Pharmaceuticals to Present at the SVB Leerink 10th Annual Global Healthcare Conference
From Business Wire News Releases
Aurinia Stock Has Great Potential, but It’s Not a Buy Right Now
Tags AUPH Market News GSK
From InvestorPlace
Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021
From Business Wire News Releases
The Math Shows BIB Can Go To $111
Tags ETFs
From ETF Channel
Earnings Preview: Aurinia Pharmaceuticals
Tags BZI/EP Earnings Benzinga
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.